 EMERYVILLE, Calif., Sept. 17, 2021 GLOBE NEWSWIRE -- Gritstone bio, Inc. Nasdaq: GRTS, a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today announced results with its SLATE v1 product off-the-shelf shared neoantigen immunotherapy in combination with intravenous nivolumab and subcutaneous ipilimumab and dosing of the first patient in a Phase 2 clinical trial of the optimized SLATE v2 product. SLATE v2 has been engineered, based on human translational immunology data from v1 patients, to drive a more potent immune response to mutant KRAS neoantigens than were observed with SLATE v1. The data from SLATE v1 will be reviewed during the companys previously announced investor event taking place today at 1:30pm ET. 